Journal of Pharmacology and Drug Metabolism

Editorial Board (JPDM)

Cheryl Blume 
Cheryl Blume 
President
Pharmaceutical Development Group, Inc.
USA
Biography
Dr. Cheryl Blume received her Ph.D. in Pharmacology and Toxicology from The West Virginia University Medical Center. Dr. Blume then worked in the U.S. pharmaceutical industry and held the executive positions of VP, Scientific Affairs (Mylan Laboratories) and Executive VP and COO (Somerset Pharmaceuticals). She has participated in over 100 ANDAs/NDAs and many IND research programs. Dr. Blume has testified before Congress, is the inventor of multiple U.S. and international patents, and is an author of peer reviewed articles. As the Founder and President of Pharmaceutical Development Group (PDG), Dr. Blume now assists FDA regulated, U.S. and international companies in the navigation of U.S. procedures. This spans a variety of product forms and therapeutic areas, including prescription and non-prescription drugs and medical devices. Dr. Blume is also an Affiliate Associate Professor to the Voluntary Faculty, Department of Molecular Pharmacology & Physiology, University of South Florida, Tampa, Florida
Publications
President
Pharmaceutical Development Group, Inc.
USA
Research Interest
Shufeng Zhou
Shufeng Zhou
Professor
University of South Florida
Associate Vice President of Global Medical Development
USA
Biography
Professor Zhou is presently the Associate Vice President of Global Medical Development & Associate Dean of International Research, College of Pharmacy, University of South Florida, Tampa (USF), Florida. USF is one of only 25 public research universities nationwide with very high research activity that is also designated as community engaged by the Carnegie Foundation for the Advancement of Teaching. USF is a global research university ranked 34th in federal research expenditures for public universities and is one of the fastest growing in federal funding in the US. Professor Zhou has published more than 350 peer-reviewed papers in various pharmacology and medical journals including New England Journal of Medicine, Cancer Research, Journal of Biological Chemistry, Clinical Pharmacology and Therapeutics, and Clinical Cancer Research. He has also published 18 books and book chapters and more than 320 conference abstracts. His work has been cited more than 9,400 times by other colleagues with an H-index of 47. Dr Zhou has given more than 120 invited seminars/keynote presentations to a variety of academic institutes, government agencies, and high-profile international conferences. He has received more than US$25.0 million grants from various funding bodies and industries. He is a recipient of several national and international awards, a council member of US Pharmacopoeia and advisor of World Health Organization (WHO), a council member or chair of several national and international professional societies, and a visiting/adjunct professor of multiple reputable research universities around the world.
Publications
Professor
University of South Florida
Associate Vice President of Global Medical Development
USA
Research Interest
Systems pharmacology, drug metabolism & drug transport, pharmacokinetics/pharmacometrics, pharmacogenomics, nanomedicine and Chinese medicine.
Paul Frederick Smith
Paul Frederick Smith
Professor
University of Otago
New Zealand
Biography
Publications
Professor
University of Otago
New Zealand
Research Interest
Sinisa Dovat
Sinisa Dovat
Director
Translational Research-Four Diamonds Pediatric Cancer Research Center
Associate Professor
Pennsylvania State University
USA
Biography
Dr. Dovat completed his clinical training in Pediatrics in Pennsylvania State University, and in Pediatric Hematology/Oncology at UCLA-Children’s Hospital. He received his research training at Cornell University Graduate School of Medical Sciences and at Howard Hughes Medical Institute at UCLA. During his postdoctoral training at UCLA, Dr. Dovat began his research on the role of Ikaros family genes in normal hematopoiesis and in leukemia. As an independent investigator at the University of Wisconsin, Dr. Dovat focused his work on the regulation of the tumor suppressor activity of Ikaros in childhood leukemia. Results of his research led to the discovery that CK2 kinase negatively regulates the tumor suppressor activity of Ikaros in leukemia and identified three signal transduction pathways that control Ikaros function: CK2 kinase, Protein Phosphatase 1 (PP1), and ubiquitination, These data provided a mechanistic basis for the use of CK2 inhibitors for treatment of hematological malignancies. Dr. Dovat is the recipient of The Young Investigator Award by The American Society of Pediatric Hematology/Oncology, and has been included in the Best Doctors in America list since 2008. His research was supported by a National Institute of Health (NIH) and the St. Baldrick’s Foundation. Since September 2010, Dr. Dovat has been serving as the Four Diamond Endowed Chair and Director of Translational Research and Developmental Therapeutics in Pediatric Hematology/Oncology at Pennsylvania State University College of Medicine, Hershey
Publications
Director
Translational Research-Four Diamonds Pediatric Cancer Research Center
Associate Professor
Pennsylvania State University
USA
Research Interest
Epigenomic regulation and transcriptional control of cellular immortalization and senescence in leukemia and experimental therapy on malignant diseases.
Ling-Zhi Wang
Ling-Zhi Wang
Senior Research Scientist
National University of Singapore
Singapore
Biography
Dr. Lingzhi Wang is a Senior Research Scientist in the Experimental Therapeutics Program and Deputy Head of Drug Analysis & Pharmacokinetics Core (DAPC) of the Cancer Science Institute of Singapore, National University of Singapore (NUS). Currently, he is also an Adjunct Assistant Professor in the Department of Pharmacology of Yong Loo Lin School of Medicine, NUS. He obtained his B.Sc. and M.Sc. in Medicinal Chemistry from Chongqing Medical University (China) in 1993. Thereafter, he joined Sichuan Centre for Disease Control and Prevention (China) as a Junior Principal Investigator in the Department of Pharmaceutical Science and was promoted to be the Deputy Head of Department in 1995. Since 1998, Dr. Wang has been working in the National University of Singapore as a Research Chemist, Research Associate and Research Fellow in Pharmaceutical Analysis, Pharmacokinetics and Cancer Pharmacology. He continued his postgraduate studies in NUS and obtained his M.Sc. in Pharmacy and Ph.D. in Pharmacology in 2003 and 2008, respectively. Dr. Wang has won Medical Research Scientist Award from National Medical Research Council (NMRC Singapore) in 2005 and PhD Graduate Research Excellence Award from AAPS Annual Meeting 2008 (USA). Till date, he has published more than 40 research papers in some reputable and premium journals such as Cell, Journal of Clinical Oncology, Clinical Cancer Research, PLOS ONE, Journal of Chromatography B, Journal of Pharmaceutical and Biomedical Analysis, Journal of Mass Spectrometry as well as Rapid Communications in Mass Spectrometry, etc. Last year, Dr. Wang was honoured to be invited to become a member of the editorial board for Current Chromatography journal. His research interest covers many aspects of the anti-cancer drug discovery and development, including preclinical and clinical pharmacokinetics studies, personalized cancer treatment and optimized combination therapy in in vitro and in vivo models.
Publications
Senior Research Scientist
National University of Singapore
Singapore
Research Interest
Cancer Pharmacology, Drug Analysis and Pharmacokinetics, Lung Cancer, Cancer Biomarkers Discovery
David Diamond
David Diamond
Professor
University of South Florida
USA
Biography
David Diamond, Ph.D., is the Director of the Center for Preclinical and Clinical Research on PTSD, Director of the USF Neuroscience Collaborative Program, and Professor of Psychology, Molecular Pharmacology and Physiology at the University of South Florida. Dr. Diamond is also a Research Career Scientist in the Medical Research and Development Service at the Tampa Veterans Hospital in Tampa, Florida, USA. Dr. Diamond was awarded his doctorate in Biology in 1985, with a specialization in Behavioral Neuroscience, from the Center for the Neurobiology of Learning and Memory and Department of Psychobiology at the University of California, Irvine. He then conducted post-doctoral research at the University of Colorado Health Sciences Center, where he developed his research program on the influence of psychological stress on the brain and memory. He is now a professor in the Departments of Psychology and Molecular Pharmacology and Physiology at the University of South Florida, and is a Career Scientist at the Tampa Veterans Hospital, where he has directed his research program on animal models of post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI), as well as clinical studies on people diagnosed with PTSD. Dr. Diamond serves as the Director of the USF Neuroscience Collaborative program and the USF Center for Preclinical Research and Clinical Research on PTSD, and is a Fellow at the American Institute of Stress. He has served on federal government study sections and committees evaluating research on the neurobiology of stress and memory, including a national program designed to develop a biologically-based diagnosis of PTSD. Dr. Diamond has approximately 100 publications and review articles on the brain and memory, including research on PTSD and Alzheimer’s disease. He serves on the editorial boards of numerous medical journals, and has received over 25 years of federally funded support for his research, including current awards from the Department of Veterans Affairs and the Department of Defense.
Publications
Professor
University of South Florida
USA
Research Interest
Neurobiology of memory and stress; Animal models of PTSD; Clinical research on PTSD – etiology, susceptibility and treatment; Nutrition, brain health and cardiovascular disease
Kunlin Jin
Kunlin Jin
Professor
University of North Texas Health Science Center
USA
Biography
Kunlin Jin, M.D., Ph.D. was trained in University of California, San Francisco and University of Pittsburg, School of Medicine. Now Dr. Jin is tenured professor at University of North Texas Health Science Center at Fort worth., USA
Publications
Professor
University of North Texas Health Science Center
USA
Research Interest
Stem cells, aging and stroke
S. Jamal Mustafa
S. Jamal Mustafa
Professor
WVU Health Sciences Center
USA
Biography
S. Jamal Mustafa received my Ph.D. in Biochemistry from Lucknow University, India in 1970. In 1971, he accepted a prestigious NIH fellowship at the University Of Virginia School Of Medicine, Charlottesville, Virginia, and stayed until 1974.He became an Assistant Professor of Pharmacology at the University of South Alabama, Mobile, Alabama (1974-1980) and was soon promoted to Associate Professor at that school in 1977. He was recruited to East Carolina University School of Medicine (1980-2005) where heremained for 25 years as a Professor of Pharmacology with appointments in the Cardiovascular Center and the Departments of Medicine and Pediatrics. He received many awards including the 1995 Helms Research Award from Sigma Xi, the First Award for Excellence in Basic Research from School of Medicine, in 1997, Lifetime Achievement Award from East Carolina. He received the Distinguished Service Award in 1996 and “Mario Toppo Distinguished Scientist Award” from Association of Scientists of Indian Origin in America in 2000 and was a recipient of the Life Time Achievement Award in Research and Creative Activities from East Carolina University in June, 2003. He have published over 190 full length manuscripts.He co-edited a book on ‘Adenosine Receptors in Health and Disease’ (with Connie Wilson) in the Handbook of Experimental Pharmacology, Volume 200, Springer- Verlag GmbH (2009). During the last many years, his lab has been involved in studies related to the regulation of vascular tone and specifically the regulation of coronary flow by adenosine receptors (AR) and its signaling using various models. Their past work was instrumental in the approval by FDA (2008) of an A2A selective AR agonist (Lexican®) for myocardial perfusion imaging. Currently, we are using A1, A2A, A2B and A3 AR and their double (A2A/A2B) KOs as well as β adrenergic receptor KOs to better understand the relationship between these receptors in the regulation of coronary flow and their signaling. Additionally, Hehave a great deal of exposure to translational aspects of my work especially in the area of cardiovascular disease and asthma.
Publications
Professor
WVU Health Sciences Center
USA
Research Interest
S. Hossein Fatemi
S. Hossein Fatemi
Professor
University of Minnesota
USA
Biography
Professor S. Hossein Fatemi completed an undergraduate degree in Biology at Baylor University in 1974. He completed a M.S. and a Ph.D. in Human Anatomy and Cell Biology at the University of Nebraska Medical Center in 1976, and 1979 respectively. Subsequently, he obtained postdoctoral fellowships at the University of Texas School of Medicine at Houston, Department of Pharmacology; the University of Texas, Cyclic Nucleotide Labs; McGill University; and the National Institutes of Health (NIH). Dr. Fatemi then completed medical studies at Case Western Reserve University in 1991. Following completion of his residency program at University Hospitals of Cleveland, he was appointed Associate Professor of Psychiatry, Cell Biology and Neuroanatomy at University of Minnesota Medical School, beginning July of 1996 and January of 1997, respectively. Here he was given the opportunity to work both as a clinician and a basic scientist to study the etiology and treatment of major mental disorders including schizophrenia, autism, bipolar disorder, and major depressive disorder. Dr. Fatemi was awarded tenure in 1999, and promoted to full professor of psychiatry and adjunct professor of neuroscience in 2006. In 2007 he was also promoted to adjunct professor of pharmacology. He is currently the Bernstein Professor in Adult Psychiatry and the Associate Chair for Neuroscience and Translational Research for the Department of Psychiatry. He has authored 106 articles and 26 book chapters and 3 books largely on his current research which focuses on the neurodevelopmental mechanisms that contribute to normal structure and function of the brain and which, under certain circumstances, cause neuropsychiatric disorders. Dr. Fatemi is involved in multiple organizations including the American College of Psychiatrists, the Society for Biological Psychiatry, the American Psychiatric Association, and the International College of Neuropsychopharmacology.
Publications
Professor
University of Minnesota
USA
Research Interest
Pharmacology
Juan Carlos Laguna Egea
Juan Carlos Laguna Egea
Professor
University of Barcelona
Spain
Biography
Dr. Juan Carlos obtained his Degree in Pharmacy in 1981 at the University of Barcelona (UB), with a Master’s with Honourable Mention in 1983. In 1986, he was awarded a PhD in Pharmacy, also from the UB, with my doctoral work winning the “1985-1986 Extraordinary Award for a Doctorate” from the School of Pharmacy. In 1987, he became Lecturer in Pharmacology at the UB, and Full Professor (Chair in Pharmacology) in 2003. In the Spanish Public University system, both positions are obtained in direct competition with other applicants after public evaluation by a tribunal composed of 5 members elected from among University academics. He was a lecture in Pharmacology at the School of Pharmacy UB, mainly focusing in the fields of Molecular Pharmacology, Biochemical Pharmacology and Cardiovascular Pharmacology. He is the coordinator of the course “Cardiovascular Pathologies and Atherosclerosis” at the Master’s in Biomedicine UB. Recently, he was appointed Director of the official Master’s “Scientific Departments of the Pharmaceutical Industry” UB/EFAME Foundation. He is also an active member of the GIDOF “Group of Innovative Teaching in Pharmacology” UB, set up in 2002. Since 2004, he has participated as coordinator and professor in several courses UB on the subject of dyslipidaemia and obesity, addressed to the general public, as well as Pharmacology Training Courses organized by the Official Pharmaceutical Organizations from Catalonia.
Publications
Professor
University of Barcelona
Spain
Research Interest
Experimental Pharmacology (atherosclerosis and related metabolic diseases), nuclear receptors, hypolipidemic drugs, experimental models of metabolic diseases
Frederick E. Williams
Frederick E. Williams
Associate Professor
University of Toledo
United States
Biography
Publications
Associate Professor
University of Toledo
United States
Research Interest
Molecular aspects of developmental and behavioral toxicities
Yi Zhun ZHU
Yi Zhun ZHU
Professor of Pharmacology
Dean, School of Pharmacy Fudan University
China
Biography
Dr. Yi Zhun Zhu got his M.D./Ph.D. at Faculty of Medicine, University of Heidelberg, Germany in 1995. He joined as a faculty member of the Department of Pharmacology, National University of Singapore (NUS) in 1998 after postdoc training at Kiel University and industrial experience at Hoechst Marion Roussel (now Sanofil). Dr. Zhu is currently a Professor of Pharmacology (also as adj-professor at Pharmacology, NUS), Dean of School of Pharmacy and Director, Institute of Drug R&D, Fudan University. Dr. Zhu published more than 100 peer-reviewed papers with more than 2300 citations and edited 2 books for his work. He is an associate editor J Alzheimer Diseases, Life Sciences and editorial board member of Biosci. Reports, J of Pharmacology and Drug Metabolism. Dr. Zhu is also editor-in-chief for the national text book of Pharmacology (7th edition, People’s Medical Publishing House), Dr. Zhu was awarded Lee Kuan Yew Research Fellowship in 1998 from Singapore, ‘distinguished Young Scientist Grant from Natural Science Foundation of China (NSFC) in 2008, Chief Scientist of National Key Research Program (973) and Chief-PI for the National Platform of Drug Discovery in 2009. Dr. Zhu further received National Award for Innovative Research Work of the Returnees in 2009 from State Council and Magnolia Award from Shanghai Government in 2010. Dr. Zhu was awarded 2011 Cheung Kong Professorship by the Ministry of Education, China. His research focuses on molecular pharmacology/drug mechanisms especially for heart and brain. Two novel compounds as drug candidates have been completed pre-clinical trials and are moving to clinical trails now.
Publications
Professor of Pharmacology
Dean, School of Pharmacy Fudan University
China
Research Interest
Molecular pharmacology/drug mechanisms especially for heart and brain. Two novel compounds as drug candidates have been completed pre-clinical trials and are moving to clinical trails now.
Khalid M. Elased
Khalid M. Elased
Associate Professor
Wright State University
United States
Biography
Publications
Associate Professor
Wright State University
United States
Research Interest
Understanding and manipulating the Renin-Angiotensin System (RAS) relevant to hypertension and diabetes, with a special interest in the use of Mass Spectrometry (SELDI-TOF-MS) to develop and optimize miniaturized novel assay to measure localized and circulating angiotensin converting enzyme (ACE ), ACE2 and renin.
Christian Waeber
Christian Waeber
Senior Lecturer in Pharmacology
University College Cork
Ireland
Biography
Christian Waeber recently relocated from Massachusetts General Hospital (MGH)/Harvard Medical School to University College Cork (UCC), where he is senior lecturer in Pharmacology, a joint appointment between the School of Pharmacy and the Department of Pharmacology. Early in his career, Dr. Waeber worked as a Ph.D. student at Novartis Basel, where he characterized the pharmacological profile, signalling pathways and brain distribution of 5-HT1D receptors. Dr. Waeber then joined as a post-doctoral fellow the “Centre CNRS-INSERM de Pharmacologie-Endocrinologie” in Montpellier. In 1993, Dr. Waeber joined MGH to characterize the pharmacological profile of 5-HT1-like receptors inhibiting neurogenic inflammation. Ten years ago, Dr Waeber switched topics, largely abandoning research on 5-HT to focus on the role of sphingosine-1-phosphate (S1P) receptors in blood vessels and brain. These blood vessel studies are significant for the treatment of cerebrovascular disorders (e.g. stroke, vasospasm), and conditions such as diabetes, atherosclerosis, pulmonary hypertension or cancer. Dr. Waeber’s team has also shown that S1P receptors have a widespread distribution both in adult and developing brain. They have characterized the CNS distribution of the S1P synthesizing enzyme, sphingosine kinase (SK), showing that it is up-regulated in neurons following ischemia. Finally, they have shown that stimulating S1P receptors with a pharmacological agent (FTY720/fingolimod) or endogenously-produced S1P (preconditioning) protects the brain from ischemia-induced damage. Finally, Dr. Waeber’s team has shown that administering fingolimod as late as 24 hours after reperfusion in a mouse model promotes long-term stroke recovery. His team has recently published that fingolimod reduces the neurological deficit and infarct volume after in situ thrombo-embolic occlusion of the middle cerebral artery, a model likely to better mimic the features of stroke in humans: combination of fingolimod and tPA improved the neurological outcome of the thrombolytic therapy and reduces the risk of hemorrhagic transformation associated to delayed administration to tPA. Christian Waeber has authored a total of 126 publications (91 peer-reviewed), cited more than 6800 times, with an H-index of 47 (Thompson Reuters Web of Science, August 2013), in the fields of neuro- and cardiovascular pharmacology, on various G Protein-Coupled and other receptors, as well as calcium channels. He has also published extensively on enzymes, and authored many reviews on antimigraine drugs, 5-HT or S1P signalling.
Publications
Senior Lecturer in Pharmacology
University College Cork
Ireland
Research Interest
Stroke, Migraine, Neuroprotection, Cerebrovascular regulation, Vascular biology, Sphingolipids
Ismail Laher
Ismail Laher
Professor
THE UNIVERSITY OF BRITISH COLUMBIA
Canada
Biography
Publications
Professor
THE UNIVERSITY OF BRITISH COLUMBIA
Canada
Research Interest
1. Vascular smooth muscle 2. Endothelium 3. Diabetes 4. Exercise 5. Obesity 6. Free radicals 7. Antioxidants 8. Autoregulation 9. Resistance arteries
Xinming Liu
Xinming Liu
Assistant Professor
University of Nebraska Medical Center
United States
Biography
Dr. Xinming Liu is an Assistant Professor in the Department of Pharmacology and Experimental Neuroscience, College of Medicine, and a courtesy faculty in the Department of Pharmaceutical Sciences, College of Pharmacy, at the University of Nebraska Medical Center (UNMC). Dr. Liu’s research mainly focuses on the development and evaluation of drug delivery systems, nanomedicine and small molecule prodrugs for the treatment of human diseases. His research is highly technology- and science-driven, with strong translational emphasis on targeted therapy of HIV/AIDS, inflammatory diseases and orofacial diseases. Dr. Liu developed targeted nano-formulated antiretroviral therapeutics (nanoART) that provide efficient HIV inhibition lasting more than 2 weeks after a single dose administration. This set of nanotechnologies has been licensed to a pharmaceutical company, NanoART LLC, which was founded in collaboration with ViiV Healthcare with the goal to develop the first long-acting nanoformulation product for HIV treatment. Other nanotechnologies that Dr. Liu developed include biomineral-binding micelles and liposomes, which were also licensed, and another pharmaceutical company Oravation LLC was founded and is currently developing several nanoformulated anti-plaque mouthwash and toothpaste products. Dr. Liu also developed polymer therapeutics based on HPMA copolymers and multifunctional PEG that provide 3-week anti-inflammatory effects with a single dose. These therapeutics have been licensed by the UNMC Technology Transfer organization (UNeMed Corp.) for the treatment of inflammatory diseases.
Publications
Assistant Professor
University of Nebraska Medical Center
United States
Research Interest
Chemically engineering novel biomaterials, drug delivery systems (DDS), nanomedicine, and low-molecular-weight prodrugs for the targeting theranostic application of HIV, CNS diseases, cancer, inflammatory diseases, and orofacial diseases
Robert Gros
Robert Gros
Scientist
Robarts Research Institute
Canada
Biography
Dr. Robert Gros is currently a scientist at the Robarts Research Institute and an associate professor in the Departments of Physiology and Pharmacology and of Medicine at Western University, London, Ontario. The focus of his research programme is to investigate the cellular/ molecular mechanisms involved in the regulation of vascular and cardiac function. With a particular interest in the role and regulation of G protein-coupled receptor signaling pathways as well as the role of both the neuronal and non-neuronal cholinergic system and their contribution under physiological and pathological conditions such as hypertension and heart failure. The Gros laboratory utilized a range of biochemical, cellular and molecular techniques as well as integrative approaches in genetically-modified mice and human subjects to gain a better understanding of development and progression of cardiovascular and metabolic diseases. Dr. Gros is the director of the Canada Foundation for Innovation-funded Laboratory for Cardiovascular and Metabolic Phenotyping. Dr. Gros continues to serve as a committee member on national granting agency review panels such as the Canadian Institutes of Health Research and the Heart and Stroke Foundation of Canada. He also has leadership roles on the Scientific Program Committees for both the Ontario Hypertension Society and Hypertension Canada. Dr. Gros has been the recipient of the Evelyn McGloin Fellowship Award and the Dr. Maureen Andrew New Investigator Award from Heart and Stroke Foundation of Ontario. He was awarded the Young Investigator Award from the Canadian Hypertension Society in 2008 and was the recipient of a New Investigator Salary Award from the Heart and Stroke Foundation of Canada.
Publications
Scientist
Robarts Research Institute
Canada
Research Interest
Hypertension, Heat Failure, G-protein coupled receptors, Cholinergic System, Steroid hormones
Howard Gu
Howard Gu
Professor
The Ohio State University
USA
Biography
Dr. Howard H. Gu is a professor in the Department of Pharmacology College of Medicine at The Ohio State University. He received his B.S and M.S. degrees from Tsinghua University, Beijing China and his Ph.D. degree in 1992 from University of Cincinnati, Ohio, USA. Dr. Gu had his postdoctoral training at Yale University in Dr. Gary Rudnick’s laboratory. He started several research projects and teaching career as an associate research scientist at Yale and as an adjunct assistant professor at School of Health Sciences, Quinnipiac University. He joined the faculty of Department of Pharmacology at OSU in 2003 as an associate professor and was promoted to a full professor in 2009.
Publications
Professor
The Ohio State University
USA
Research Interest
Molecular mechanisms of psychiatric disorders, including Substance Use Disorders / Addictive Disorders, Autism Spectrum Disorders, Depression, etc.
Martin G. Sirois
Martin G. Sirois
Professor
Université de Montréal
Canada
Biography
Martin G. Sirois, PhD, is a senior researcher at the Montreal Heart Institute Research Centre and a full professor in the Department of Pharmacology in the Faculty of Medicine at Université de Montréal. Dr. Sirois specializes in cellular and vascular biology. His main research focus is on the role of various growth factors such as vascular endothelial growth factor (VEGF) and angiopoietins (Ang1 and Ang2) in the recruitment of circulating inflammatory cells and angiogenic processes, such as those observed in the development of atherosclerosis, solid tumour growth and other vascular pathologies.
Publications
Professor
Université de Montréal
Canada
Research Interest
• Cellular and vascular biology, Gene therapy, Growth factors, Histology and immunohistochemistry, Inflammation, Angiogenesis, Biomarkers, Heart failure
Santhi Gorantla
Santhi Gorantla
Assistant Professor
University of Nebraska Medical Center
USA
Biography
Dr. Santhi Gorantla is an Assistant Professor in the Department of Pharmacology and Experiment Neuroscience at University of Nebraska Medical Center (UNMC), Omaha, NE. She has been a faculty member since 2007. Dr. Gorantla got her M.Sc. in Biochemistry and pursued Ph.D. in Immunology at University of Hyderabad, India. She got her first postdoctoral training in Gene therapy strategies for HIV in humanized mouse models at Colorado State University, and her second postdoctoral training was on the HIV-1 induced neuropathogenesis in humanized mouse models and immune modulatory therapeutic approaches. Dr. Gorantla’s research focuses on HIV-1 pathobiology, therapeutic approaches to target brain HIV-1 reservoirs, immunomodulatory approaches to reduce inflammation. Using a novel humanized mouse model of chronic HIV-1 infection, Dr. Gorantla studies immunopathology, neuropathology and therapeutics. Humanized mice with human immune system are developed by transplanting human CD34+ stem cells from umbilical cord blood at birth. She has published more than 30 peer reviewed journal articles and contributed to five book chapters. Dr. Gorantla is actively involved in teaching Pharmacology courses and drugs abuse on Immune system to graduate students. Currently her work is funded by National Institute of Health and Nebraska Stem Cell grants.
Publications
Assistant Professor
University of Nebraska Medical Center
USA
Research Interest
HIV-1, inflammation, neuropathology, humanized mice, nanoparticles, cannabinoids, anti-retrovirals, induce pluripotent cells, stem cells.
Xiaoqiang Xiang
Xiaoqiang Xiang
Associate Professor
Fudan University
China
Biography
Dr. Xiang is currently an Associate Professor in the Department of Clinical Pharmacy, School of Pharmacy, Fudan University. He earned his B.S. in pharmaceutics from School of Pharmacy, Peking University and M.S. in Pharmacy from National University of Singapore. During 2005-2006, he worked as a research officer in Department of Clinical Pharmacology, National Cancer Centre Singapore where he conducted pharmacogenomic research of anticancer drugs and anticoagulant drugs. His research findings about the influence of SLCO1B1 polymorphism on the disposition of irinotecan in Asian cancer patients has been cited by the white paper of drug transporters. In 2007, he joined CombinatoRx Pte. Ltd. and worked as a DMPK scientist in the field of drug metabolism and drug-drug interactions. In 2008, Dr. Xiang moved to Finland to pursue his Ph.D degree under the supervision of Professor Pertti Neuvonen and Professor Mikko Niemi in the Department of Clinical Pharmacology, University of Helsinki. His Ph.D. research on the identification of the genetic factors contributing to the levels of endogenous bile acids and pharmacokinetics of therapeutic ursodeoxycholic acid won him Helsinki Biomedicum Funding award. Till now, he has published over 10 peer-reviewed papers in the field of clinical pharmacology.
Publications
Associate Professor
Fudan University
China
Research Interest
Pharmacogenomic research of drug metabolizing enzymes and drug transporters, drug-drug interaction involving traditional Chinese medicine, and physiologically based pharmacokinetic modeling.
Wissam AbouAlaiwi
Wissam AbouAlaiwi
Assistant Professor
The University of Toledo
USA
Biography
Dr. Wissam AbouAlaiwi is a Visiting Assistant Professor in the Department of Pharmacology at the College of Pharmacy and Pharmaceutical Sciences at the University of Toledo (UT), Toledo, OH, where he serves as a faculty member since 2007. Dr. AbouAlaiwi got his postdoctoral training 2007-2012 in Dr. Surya Nauli’s lab in the department of Pharmacology at UT. He received his B.Sc. in Biology from the Lebanese University (LU, 2000), M.Sc. in Biology from the American University of Beirut (AUB, 2002), and Ph.D. in Biology from the University of Toledo (UT) in 2007. Dr. AbouAlaiwi has been awarded a Certificate of Appreciation from the Dean of the College of Pharmacy and Pharmaceutical Sciences for his excellence in Research publications. Dr. AbouAlaiwi’s research focuses on topics directly related to cardiovascular disease including hypertension, aneurysm formation, and cardiac hypertrophy. He studies the onset of cardiovascular complications mainly due to Polycystic Kidney Disease, the most common human genetic disorder. His main areas of research are molecular pharmacology to study the function of a cellular organelle, primary cilia and its involvement in cardiovascular and kidney function. Dr. AbouAlaiwi uses an array of sophisticated methodology to answer his research questions. These include light, fluorescent and electron microscopy, Spectral Karyotyping, Western and Immunohistochemical analyses, DNA and RNA expression analyses and others. Dr. AbouAlaiwi has authored several Refereed research papers and book chapters in high quality cardiovascular and scientific journals such as Circulation journal (Ranked #1 in cardiovascular field with an Impact factor of 15.2), Circulation Research (Ranked #2 in Cardiovascular field after Circulation), and Human Molecular Genetics. His research was consecutively featured on the Covers of Circulation Research and Human Molecular Genetics. Dr. AbouAlaiwi is also involved in teaching Pharmacology courses to undergraduate, graduate and Pharm.D students. He has also mentored several undergraduate and graduate students in research theses and activities.
Publications
Assistant Professor
The University of Toledo
USA
Research Interest
Tuan Trang
Tuan Trang
Assistant Professor
University of Calgary
Canada
Biography
Dr. Trang received a PhD in Pharmacology and Toxicology from Queen’s University, Canada, where he studied the spinal mechanisms of opioid opioid tolerance and physical dependence. He then pursued postdoctoral training in the laboratory of Dr. Michael Salter at Sick Kids Hospital in Toronto. There he expanded his area of expertise into the cellular and molecular study of chronic pain. Dr. Trang is an assistant professor at the University of Calgary in the Faculties of Veterinary Medicine and Medicine, and he is a full member of the Hotchkiss Brain Institute. His research program investigates the critical molecules and processes involved in pain and how these processes can go awry to produce chronic pain. A focus of his research is on use of opioid drugs in treating chronic pain conditions.
Publications
Assistant Professor
University of Calgary
Canada
Research Interest
Pain; Opioid Pharmacology; Microglia; Purinergic Signaling
Manuel Vázquez-Carrera
Manuel Vázquez-Carrera
Associate Professor
University of Barcelona
Spain
Biography
Dr Manuel Vázquez-Carrera obtained his Pharmacy degree at the University of Barcelona in 1990 with A mark. In 1991 he got a grant FPI of the Generalitat de Catalunya (for the period 1991-1994) for young researchers. Since then he has been working, as a research student at the Department of Pharmacology of the Faculty of Pharmacy of Barcelona. He finished his Ph.D. in December 1994. In 1995 Dr Vázquez-Carrera obtained a grant of the European Science Foundation for 1 year to perform a postdoctoral stage in the PPAR field at the Institut de Biologie Animale, Université de Lausanne, Switzerland under the supervision of Dr. Walter Wahli. Currently, Dr. Vázquez-Carrera is a Lecturer in Pharmacology at the Faculty of Pharmacy of the University of Barcelona.
Publications
Associate Professor
University of Barcelona
Spain
Research Interest
• Inflammation and insulin resistance • Experimental models of Metabolic Syndrome: the fructose-fed rat and senescence-related models in rodents. Molecular basis and drug activity. • Molecular basis of insulin resistance in skeletal muscle and modulation by drugs. • Molecular basis of cardiac hypertrophy: Role of PPARs and inflammation-related Transcription Factors.
Nikhil Adi
Nikhil Adi
Assistant Scientist
Miller School of Medicine
University of Miami
United States
Biography
Dr. Nikhil Adi is an Assistant Scientist in the Department of Molecular and Cellular Pharmacology and the Vascular Biology Institute at the Miller School of Medicine, University of Miami, Miami, FL. Dr. Adi got his Ph.D. from the Maharaja Sayajirao University of Baroda, Baroda, India in 2005. Dr. Adi has also worked as a Teaching Assistant at the Maharaja Sayajirao University of Baroda, India. Subsequent to his Ph.D. Dr. Adi worked in pharmaceutical companies on G-protein coupled receptors as a therapeutic for treating obesity. Dr. Adi got his first postdoctoral training in gene expression profiling working on human postmortem brain tissue from Drug Addicts and Parkinson’s disease patients. At present Dr. Adi’s research focuses on microRNA and gene expression profiling of insulin resistant tissues in a new mouse model with polygenic susceptibility for type 2 diabetes. This study analyzes the involvement of diet on development/prevention of obesity/diabetes in this new animal model and also aims to establish a molecular profile for altered microRNAs in the insulin resistant tissues. Dr. Adi is also serving as a reviewer for several peer reviewed journals.
Publications
Assistant Scientist
Miller School of Medicine
University of Miami
United States
Research Interest
Molecular mechanism of insulin resistance, microRNA s in Obesity and Diabetes, Role of diet in Obesity and Diabetes, Gene expression profiling in human post mortem brain, Molecular basis of drug addiction
Austin M Guo
Austin M Guo
Assistant professor
New York Medical College
USA
Biography
Dr. Austin Guo, PhD, is currently an Assistant Professor of Pharmacology at New York Medical College. He received his B.S. in Biotechnology from St Cloud State University in Minnesota, USA and his PhD in Cancer Biology from Wayne State University in Michigan, USA. Dr. Guo completed two years of postdoctoral work at Wayne State University after his graduation and took a junior research staff position at Henry Ford Hospital from 2003-2007. He was then raised the rank to Assistant Scientist in 2007 and held that position until he joined the faculty in New York Medical College in 2011. Dr. Guo’s research focused on investigating the role of Cytochrome P450 derived eicosanoids, specifically 20-hydroxyeicosatetraenoic acid (20-HETE), in the regulation angiogenesis and cancer growth. Currently, Dr. Guo is trying to understand how 20-HETE system contributes to neovascularization via up-regulation of the human umbilical cord blood derived Endothelial progenitor Cells functions that are associated with angiogenesis. This work is supported by a Scientist Development Award grant from American Heart Association.
Publications
Assistant professor
New York Medical College
USA
Research Interest
Studying the role of stem cell derived eicosanoids in regulation of cancer and ischemia mediated angiogenesis
Andrea LIM Yun-An
Andrea LIM Yun-An
YLL School of Medicine
National University of Singapore
Singapore
Biography
Publications
YLL School of Medicine
National University of Singapore
Singapore
Research Interest
Alzheimer’s disease, diabetes mellitus, mitochondrial dysfunction, amyloid-beta, amylin, neurotoxicity
Liqin Zhao
Liqin Zhao
Assistant Professor
University of Kansas School of Pharmacy
USA
Biography
Dr. Zhao received her PhD in Pharmaceutical Sciences from Shenyang Pharmaceutical University in China in 1999 and continued her postdoctoral research in neuroscience at the Beijing Institute of Pharmacology and Toxicology. Dr. Zhao joined the University of Southern California in 2002 and most recently served as a Research Associate Professor of Pharmacology & Pharmaceutical Sciences and Director of Core Facilities & Services in the School of Pharmacy. In August 2013, Dr. Zhao joined the faculty as a Tenure-Track Assistant Professor in the Department of Pharmacology and Toxicology at the University of Kansas School of Pharmacy. Dr. Zhao has served as a principal investigator or co-investigator on a number of research projects funded by the Alzheimer’s Association and National Institute on Aging. In recognition of her work on estrogen receptor (ER) beta and achievement in bench to bedside translational development of an ERbeta-selective therapy (two patents granted and one pending) that is currently under evaluation in a phase I/IIa clinical trial, Dr. Zhao was chosen as one of five researchers profiled in the Alzheimer’s Association’s annual report: The Year in Alzheimer Science 2010. Moreover, Dr. Zhao is recognized by the Association under: Spotlight on Researchers Dedicated to Alzheimer’s
Publications
Assistant Professor
University of Kansas School of Pharmacy
USA
Research Interest
Research, focusing on neurobiology of aging and neurodegeneration (with an emphasis on Alzheimer’s disease; AD), aims: • At the basic level, to understand the neurobiological effects of sex hormones and the molecular basis underlying sex differences in the risk of developing AD. Some particular areas of interest include: menopause/perimenopause, estrogen receptor beta, insulin/IGF signaling, insulindegrading enzyme, energy metabolism, apolipoproteins, and gene expression and regulation. • At the translational level, to advance basic scientific findings into therapeutic development for prevention and early intervention of pathological brain aging and neurodegeneration. Some particular areas of focus include: non-hormonal alternative therapies, estrogen receptor beta modulators, phytochemicals, and lifestyles in modulation of aging health.
Kazuko Sakata
Kazuko Sakata
Assistant Professor
University of Tennessee Health Science Center
USA
Biography
Dr. Kazuko Sakata completed an undergraduate degree in Pharmacology at Osaka University in Japan in 1995. She completed a M.S. and a Ph.D. for medical science at the graduate school of Medicine at Osaka University 1997 and 2001, respectively. She obtained postdoctoral training at National Institute of Health (NIH), Neural Development and Plasticity. Dr. Sakata was awarded the Fellows Award of Research Excellence at the NIH FARE competition and the 1st price of poster competition at the second annual meeting of the National Institute of Child Health and Development (NICHD). After working at NIIH as a Research Scientist, Dr. Sakata then joined University of Tennessee Health Science Center in Memphis as an Assistant Professor of Pharmacology/Psychiatry in September 2008.
Publications
Assistant Professor
University of Tennessee Health Science Center
USA
Research Interest
Dr. Kazuko Sakata research focuses to study neurotrophic mechanisms in neuropsychiatric conditions. In particular, her recent research focuses on the roles of gene regulation of brain-derived neurotrophic factor (BDNF) in pathogenesis of major depression and its recovery. Dr. Kazuko Sakata uses a multidisciplinary approach from genes to behavior with genetic, molecular, biochemical, electrophysiological, and behavioral techniques. While major depression is the leading disease burden in industrialized countries including the North America, she hopes that understanding the underlying mechanisms will advance the future therapy for depression.
Mohammed A. Nayeem
Mohammed A. Nayeem
Assistant Professor
West Virginia University
USA
Biography
Dr. Mohammed Nayeem is an Assistant Professor in the Department of Physiology & Pharmacology, Center for Cardiovascular & Respiratory Sciences, School of Medicine, West Virginia University, Morgantown, WV 26506, USA. He is also an Adjunct Assistant Professor in the Department of Pharmaceuticals and Pharmacological Sciences, School of Pharmacy, West Virginia University, Morgantown, WV 26506, USA. He obtained his B.Sc., M.Sc. and PhD in Life Science/Biochemistry/Immunology from Osmania University, Hyderabad, India. He worked in Medical College of Virginia, Virginia Commonwealth University, VA, USA, Brody School of Medicine, East Carolina University, NC, USA and NIEHS/NIH, NC, USA. Recently, he got his R01 funded as a Principal Investigator with excellent score from NHLBI/NIH (2013) on Role of Cyp2j-epoxygenases, sEH and PPARs in adenosine-induced vascular response. Also he got his other R01 funded as a CO-Investigator with also excellent score from NHLBI/NIH (2008) on Role of CYP P450s in the Regulation of Vascular Tone through Adenosine Receptors. Dr. Nayeem has got many other awards and honors. He has published many research papers in reputed and peer-reviewed journals related to cardiovascular pharmacology, cardiovascular physiology and in Molecular Cellular Biochemistry, Naunyn Schmiedebergs Archives Pharmacology, Journal Molecular Cellular Cardiology, Antioxidant Redox Signaling, etc. He is member of various societies including American Heart Association, American Physiology Society, International Society of Heart Research (American Section), American Society for Pharmacology and Experimental Therapeutics, Microcirculatory Society. He also reviewed many articles on Ad hoc basis related to American Journal Physiology (Heart and Circulatory Physiology), Journal of Molecular and Cellular Cardiology, Antioxidants & Redox Signaling, Journal of Cellular and Molecular Medicine, American Journal of Hypertension, International Journal of Toxicology, European Journal of Pharmacology, Nutrition, Metabolism & Cardiovascular Diseases, Drug Metabolism and Disposition, Vascular Pharmacology, Neuropharmacology. His research interest covers many aspects of Cardiovascular Pharmacology including Role of adenosine receptors in the regulation of vascular tone through cyp-epoxygenases, soluble epoxide hydrolase and omega hydroxylase; the regulation of vascular tone through the generation of EETs, DHETs and 20-HETE; the regulation of vascular tone through the adenylyl cyclase cAMP and PKA signaling; the regulation of vascular tone through peroxisome proliferator-activated receptors (PPARs); the regulation of vascular tone through ATP-sensitive (KATP) channels.
Publications
Assistant Professor
West Virginia University
USA
Research Interest
Cardiovascular Pharmacology including Role of adenosine receptors in the regulation of vascular tone through cyp-epoxygenases, soluble epoxide hydrolase and omega hydroxylase; the regulation of vascular tone through the generation of EETs, DHETs and 20-HETE; the regulation of vascular tone through the adenylyl cyclase cAMP and PKA signaling; the regulation of vascular tone through peroxisome proliferator-activated receptors (PPARs); the regulation of vascular tone through ATP-sensitive (KATP) channels.
Robert W. Brock
Robert W. Brock
Associate Professor
West Virginia University
USA
Biography
Dr. Robert Brock is an Associate Professor of Physiology & Pharmacology at West Virginia University, and has served as Director of the Cellular & Integrative Physiology Graduate Program since July of 2009. As Graduate Director, he leads a group of energetic faculty intent on engaging students in creating a new approach to the life sciences with the aim of explaining how the higher-level properties of complex biological systems interact and function. Dr. Brock earned his Ph.D. in Medical Biophysics from the University of Western Ontario in Canada, and completed a Natural Sciences and Engineering Research Council of Canada Fellowship at the Lawson Health Research Institute. Prior to joining WVU, Dr. Brock was an Assistant Professor of Pharmacology & Toxicology at the University of Arkansas for Medical Sciences. His research interests center on determining the mechanisms of microvascular and endothelial dysfunction that accompany various inflammatory and oxidative conditions, specifically diabetes and obesity. The American Heart Association and the NIDDK have funded Dr. Brock’s research on diabetic microvascular dysfunction over the past decade. He has served on numerous international and national study sections and editorial boards. Dr. Brock has held other leadership roles within the American Physiological Society, American Society for Pharmacology & Experimental Therapeutics and the Microcirculatory Society. He recently was elected Fellow of the Basic Cardiovascular Sciences Council of the American Heart Association.
Publications
Associate Professor
West Virginia University
USA
Research Interest
Regulation of microvascular function; inflammation; oxidative stress

top